#kisqali

Of course the first thing I did was to search for first-person accounts of people taking the drug on my Facebook groups, Instagram, Reddit and TikTok and found horror stories of weird rashes, exhaustion, inflamed livers and more. But then, who said any of this is going to be easy? Today is also Manav's birthday, so I am thinking of this as the best birthday gift I could possibly give him: a longer life together. Here is a good one I found online:

This is a social media monitoring report on US FDA approval of Kisqali (ribociclib) a drug of Novartis for the treatment of Advanced Breast Cancer. Kisqali social media listening report intended to cover following points:

Quantitative Analysis

Quantitative analysis done to map share of online conversation about the approval news on various social media channels.

Dominant media type for Kisqali approval new.

Topic trend or buzz trend during the monitoring period

Top keywords discussed in association with Kisqali through conversation cloud analysis

Top hostages and mentions

Qualitative analysis

A high level sentiment analysis to understand people perception and sentiment about the drug’s approval.

Top KOLs and interesting verbatim are covered

Request For samples & inquires please drop me a message at [email protected]

Scope to improve on the study

A detailed qualitative analysis can be done to understand people perception and sentiment about any specific topics or attributes such. Here is what can be covered in the detailed analysis:

Participant’s profiling

Perceptions and sentiment by participant type

Perceptions and sentiment by attributes such as clinical trial result, efficacy or safety profile, Insurance coverage, etc.

Get Customized Newly Research Social Media Monitoring Report on Kisqali Report : http://www.socioinsider.com/Brand_Monitoring?product_id=132

Any specific challenges patients are facing

Reasons, patient might consider Kisqali for their treatment

Barriers and drivers

What good looks like and what bad looks like

Any campaign/initiative by manufacturer or counter initiatives by competitors and its effectiveness

Any other relevant topic which might come across during the research

Study Background:

Monitoring period: 1st March till 15th June 17

Number of Post Analyzed (N): 1233

Geography covered: USA Only

7 Obat Baru yang Disetujui FDA di Bulan Maret 2017

farmasetika.com – Regulator obat dan makanan Amerika Serikat (Food and Drug Administration/FDA) telah merilis 7 obat baru yang disetujui pada bulan Maret 2017. Obat itu adalah Bavencio, Dupixent, Keytruda, Kisqali, Noctiva, Xadago, dan Zejula.

1. Bavencio

FDA memberikan persetujuan yang dipercepat untuk avselabasi dari EMD Serono (Bavencio) pada tanggal 23 Maret 2017.

Bavencio diindikasikan untuk…

March 13, 2017

Novartis has gained the FDA approval for LEE011, its CDK 4/6 drug now approved as a frontline therapy for postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer in combination with any aromatase inhibitor. Also known as ribociclib, the drug hits the market as Kisqali with peak sales estimates of…